Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’
Jim Cramer favors Texas Pacific Land, calls Kailera his speculative pick, and criticizes P&G, Ondas and Tractor Supply.
Stocks · News reference
Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.
8-K filing — Kailera Therapeutics, Inc. (KLRA)
Filed: 2026-08-12 AccNo: 0001193125-26-346919 Size: 411 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits